中国医学前沿杂志(电子版)
中國醫學前沿雜誌(電子版)
중국의학전연잡지(전자판)
CHINESE JOURNAL OF THE FRONTIERS OF MEDICAL SCIENCE(ELECTRONIC VERSION)
2014年
11期
71-73
,共3页
拉贝洛尔%硫酸镁%地屈孕酮%重症子痫
拉貝洛爾%硫痠鎂%地屈孕酮%重癥子癇
랍패락이%류산미%지굴잉동%중증자간
Rabe noel%Magnesium sulfate%Flexor progesterone%Severe preeclampsia
目的:探讨拉贝洛尔、硫酸镁联合地屈孕酮治疗早发型重症子痫前期的临床效果及安全性。方法将98例早发型重症子痫前期孕妇随机分为治疗组和对照组,每组各49例。对照组患者采用拉贝洛尔联合硫酸镁治疗,治疗组患者在对照组基础上采用地屈孕酮治疗,比较两组患者治疗前与治疗1周后收缩压(SBP)、舒张压(DBP)、疗效、不良反应发生情况及最后的分娩方式、妊娠结局。结果治疗前两组患者SBP、DBP组间比较差异均无显著性(P>0.05);治疗后两组患者SBP、DBP均较治疗前明显好转,且治疗组优于对照组,差异均具有显著性(P<0.05);治疗组显效27例(55.1%),有效20例(4.82%),无效2例(4.08%),总有效率为95.92%;对照组显效19例(38.78%),有效21例(42.86%),无效8例(18.37%),总有效率为81.63%,两组患者总有效率比较差异具有显著性(P<0.05);治疗组患者不良反应发生率(12.24%)明显低于对照组(28.57%),差异具有显著性(P<0.05);治疗组患者顺产36例(73.47%),剖宫产10例(20.41%),对照组分别为22例(44.90%)、19例(38.78%),两组比较差异具有显著性;两组患者妊娠结局比较差异均无显著性(P>0.05)。结论拉贝洛尔、硫酸镁联合地屈孕酮治疗早发型重症子痫前期效果明显优于拉贝洛尔联合硫酸镁,且不良反应发生率更低,值得临床推广应用。
目的:探討拉貝洛爾、硫痠鎂聯閤地屈孕酮治療早髮型重癥子癇前期的臨床效果及安全性。方法將98例早髮型重癥子癇前期孕婦隨機分為治療組和對照組,每組各49例。對照組患者採用拉貝洛爾聯閤硫痠鎂治療,治療組患者在對照組基礎上採用地屈孕酮治療,比較兩組患者治療前與治療1週後收縮壓(SBP)、舒張壓(DBP)、療效、不良反應髮生情況及最後的分娩方式、妊娠結跼。結果治療前兩組患者SBP、DBP組間比較差異均無顯著性(P>0.05);治療後兩組患者SBP、DBP均較治療前明顯好轉,且治療組優于對照組,差異均具有顯著性(P<0.05);治療組顯效27例(55.1%),有效20例(4.82%),無效2例(4.08%),總有效率為95.92%;對照組顯效19例(38.78%),有效21例(42.86%),無效8例(18.37%),總有效率為81.63%,兩組患者總有效率比較差異具有顯著性(P<0.05);治療組患者不良反應髮生率(12.24%)明顯低于對照組(28.57%),差異具有顯著性(P<0.05);治療組患者順產36例(73.47%),剖宮產10例(20.41%),對照組分彆為22例(44.90%)、19例(38.78%),兩組比較差異具有顯著性;兩組患者妊娠結跼比較差異均無顯著性(P>0.05)。結論拉貝洛爾、硫痠鎂聯閤地屈孕酮治療早髮型重癥子癇前期效果明顯優于拉貝洛爾聯閤硫痠鎂,且不良反應髮生率更低,值得臨床推廣應用。
목적:탐토랍패락이、류산미연합지굴잉동치료조발형중증자간전기적림상효과급안전성。방법장98례조발형중증자간전기잉부수궤분위치료조화대조조,매조각49례。대조조환자채용랍패락이연합류산미치료,치료조환자재대조조기출상채용지굴잉동치료,비교량조환자치료전여치료1주후수축압(SBP)、서장압(DBP)、료효、불량반응발생정황급최후적분면방식、임신결국。결과치료전량조환자SBP、DBP조간비교차이균무현저성(P>0.05);치료후량조환자SBP、DBP균교치료전명현호전,차치료조우우대조조,차이균구유현저성(P<0.05);치료조현효27례(55.1%),유효20례(4.82%),무효2례(4.08%),총유효솔위95.92%;대조조현효19례(38.78%),유효21례(42.86%),무효8례(18.37%),총유효솔위81.63%,량조환자총유효솔비교차이구유현저성(P<0.05);치료조환자불량반응발생솔(12.24%)명현저우대조조(28.57%),차이구유현저성(P<0.05);치료조환자순산36례(73.47%),부궁산10례(20.41%),대조조분별위22례(44.90%)、19례(38.78%),량조비교차이구유현저성;량조환자임신결국비교차이균무현저성(P>0.05)。결론랍패락이、류산미연합지굴잉동치료조발형중증자간전기효과명현우우랍패락이연합류산미,차불량반응발생솔경저,치득림상추엄응용。
Objective To explore the clinical effect and safety of rabe noel, magnesium sulfate dydrogesterone treatment on early-onset severe preeclampsia. Method 98 cases of early onset severe preeclampsia in pregnant women were randomly divided into treatment group and control group, 49 cases in each group. Control group were treated by rabe noel joint magnesium sulfate treatment, treatment group patients on the basis of control group with lfexor progesterone therapy, compared two groups of patients before and after 1 week treatment systolic blood pressure (SBP), diastolic blood pressure (DBP), curative effect, adverse reaction and the ifnal way of delivery and pregnancy outcome. Result Before treatment the SBP, DBP between two groups had no signiifcant differences (P>0.05);two groups after treatment with SBP, DBP had signiifcant difference compared with before treatment (P < 0.05), blood pressure in both groups after treatment significantly improved than before treatment, and treatment group was better than that of control group, the comparison between groups had signiifcant difference (P<0.05);treatment group 27 cases (55.1%) were markedly improved, 20 cases (4.82%) were effective, 2 cases (4.08%) were invalid, the total effective rate was 95.92%;control group 19 cases were markedly improved (38.78%), 21 cases (42.86%) were effective, 8 cases (18.37%) were invalid, the total effective rate was 81.63%, total effective rate in both groups had signiifcant difference (P<0.05);incidence of adverse reactions in treatment group (12.24%) was obviously lower than control group (28.57%), with signiifcant difference (P<0.05);natural labor 36 cases (73.47%) in treatment group, 10 cases (20.41%) of cesarean section, control group were 22 cases (44.90%), 19 cases (38.78%), two groups had signiifcant difference (P < 0.05);two groups of patients pregnancy outcomes showed no significant difference (P > 0.05). Conclusion Rabe noel, magnesium sulfate dydrogesterone treatment of early-onset severe preeclampsia is better than noel combined with magnesium sulfate rabe, has a lower incidence of adverse reactions, worthy of clinical application.